Agrochemicals company Astec Lifesciences announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: The Company reported consolidated total income of Rs 120.3 crore in Q4FY25 as compared to Rs 155.8 crore in Q4FY24. Sequentially, the consolidated total income in Q4FY25 was higher by 25.6% over Q3FY25. The Company reported consolidated EBITDA of Rs 6.3 crore in Q4FY25 as compared to Rs 14.8 crore in Q4FY24. EBIDTA for Q4FY25 showed a sequential improvement over Q3FY25. PAT: Rs -16.1 crore compared to Rs -40.4 crore during Q3FY25. FY25 Financial Highlights: The Company reported consolidated total income of Rs 386.9 crore in FY25 as compared to Rs 463.8 crore in FY24. The Company reported consolidated EBITDA loss of Rs 60.6 crore in FY25 as compared to loss of Rs 0.3 crore in the same period last year. N. B. Godrej, Chairman, Astec LifeSciences, said: In Q4 FY25 Astec reported sequential improvement in performance. EBITDA for Q4FY25 at Rs 6.8 crore showed an improvement over the earlier quarters. This positive trend was primarily due to increase in volumes and prices in Enterprise business coupled with improved product mix in the CDMO business. We expect uptick in the demand for Enterprise & CDMO businesses and a gradual improvement in the performance in the coming year. Result PDF